Evolutionary Tree Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Evolutionary Tree Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-59,411	Closed	-$1.5M	–	37
2023 Q2	$1.5M	Sell	59,411 -7,414	-11%	-$231K	1.81%	20
2023 Q1	$2.15M	Sell	66,825 -113,829	-63%	-$3.55M	2.98%	13
2022 Q4	$3.33M	Sell	180,654 -11,214	-6%	-$257K	3.2%	13
2022 Q3	$5.18M	Buy	191,868 +57,680	+43%	+$1.17M	4.98%	6
2022 Q2	$1.85M	Sell	134,188 -42,148	-24%	-$649K	2.02%	25
2022 Q1	$3.44M	Sell	176,336 -72,197	-29%	-$1.09M	2.39%	22
2021 Q4	$4.06M	Buy	248,533 +81,342	+49%	+$1.36M	1.95%	24
2021 Q3	$4.66M	Buy	167,191 +12,476	+8%	+$356K	2.07%	23
2021 Q2	$4.59M	Buy	154,715 +4,702	+3%	+$136K	2.12%	22
2021 Q1	$4.19M	Buy	150,013 +60,665	+68%	+$1.68M	2.48%	20
2020 Q4	$2.53M	Buy	+89,348	New	+$2.31M	1.93%	22

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Evolutionary Tree Capital Management's RVNC Position: Q3 2023 in Review

Evolutionary Tree Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2023, closing a stake of 59,411 shares — an estimated $1.5M sold.

Evolutionary Tree Capital Management first reported a position in RVNC in Q4 2020 and held it in 11 quarters. The position peaked at $5.18M in Q3 2022. 186 funds tracked by Wall St. Rank hold RVNC as of Q3 2023.

Evolutionary Tree Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q3 2023 after selling out during the quarter.
Evolutionary Tree Capital Management sold 59,411 Revance Therapeutics, Inc. shares in Q3 2023, an estimated $1.5M.
Evolutionary Tree Capital Management first reported a position in Revance Therapeutics, Inc. in Q4 2020 and held it in 11 quarters.
Evolutionary Tree Capital Management's Revance Therapeutics, Inc. position peaked at $5.18M in Q3 2022.
186 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2023.

Based on Evolutionary Tree Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.